FIL Ltd Increases Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

FIL Ltd lifted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 48.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 201,376 shares of the medical device company's stock after purchasing an additional 65,984 shares during the period. FIL Ltd owned about 0.31% of Tandem Diabetes Care worth $7,254,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Tandem Diabetes Care by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock worth $267,989,000 after buying an additional 77,451 shares in the last quarter. State Street Corp raised its holdings in Tandem Diabetes Care by 3.2% in the 3rd quarter. State Street Corp now owns 2,655,736 shares of the medical device company's stock valued at $112,630,000 after acquiring an additional 83,172 shares during the last quarter. GW&K Investment Management LLC raised its holdings in Tandem Diabetes Care by 18.0% in the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock valued at $76,488,000 after acquiring an additional 323,674 shares during the last quarter. Stephens Investment Management Group LLC lifted its stake in Tandem Diabetes Care by 22.1% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company's stock worth $56,040,000 after purchasing an additional 281,327 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Tandem Diabetes Care by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,533,828 shares of the medical device company's stock worth $55,261,000 after purchasing an additional 8,012 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently commented on TNDM. Sanford C. Bernstein downgraded Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Barclays reduced their price target on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Mizuho started coverage on shares of Tandem Diabetes Care in a report on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price objective for the company. Canaccord Genuity Group reaffirmed a "buy" rating and set a $63.00 target price on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Finally, Robert W. Baird dropped their price target on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th. Nine research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat, Tandem Diabetes Care has a consensus rating of "Moderate Buy" and a consensus target price of $43.88.

Insider Transactions at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the purchase, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.20% of the company's stock.

Tandem Diabetes Care Stock Down 2.3 %

TNDM traded down $0.40 on Friday, hitting $16.86. 1,132,393 shares of the company were exchanged, compared to its average volume of 1,502,106. The firm has a 50-day moving average price of $22.10 and a two-hundred day moving average price of $30.28. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -8.74 and a beta of 1.52.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.